7:56 PM
 | 
Jun 03, 2013
 |  BC Extra  |  Clinical News

Sanofi drops two Phase III compounds

Sanofi (Euronext:SAN; NYSE:SNY) said on Monday it discontinued development of two Phase III compounds: iniparib ( BSI-201), which was in development to treat non-small cell lung cancer (NSCLC) and ovarian cancer; and otamixaban ( XRP0673), which was in development to treat acute coronary syndrome (ACS). In the Phase III ECLIPSE trial to treat...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >